INFORCE 3 is the first and only intranasal respiratory vaccine that prevents respiratory disease cause by BRSV, while also aiding in the prevention of IBR and PI3, to help get cattle off to a healthier, more productive start.
INFORCE 3 has seen continued improvements since its approval in 2010, including a six-month duration of immunity claim for infectious bovine rhinotracheitis (IBR) protection, and a single nostril administration claim. Additonal research also demonstrated no maternal antibody interference for IBR and bovine respiratory syncytial virus (BRSV).2,3
Proven Respiratory Disease Protection
- All calves vaccinated with INFORCE 3 survived a severe BRSV challenge in which all unvaccinated controls died.4,5
- North Dakota research demonstrated that vaccination with INFORCE 3 at birth improved immune response when boosted at preweaning with a combination respiratory vaccine (BOVI-SHIELD GOLD ONE SHOT).6
- Additionally, INFORCE 3 was shown to help prevent respiratory disease caused by IBR and PI3, and reduce level and duration of IBR and PI3 viral shedding.7,8,9
- Current research comparing INFORCE 3 and TSV-2 has demonstrated that vaccinating cows and heifers for BRSV prior to freshening may support overall positive production:
- 205 pounds more milk per cow per lactation10
- $36 greater income per cow10
- For dairy herds, INFORCE 3 can be used in newborn calves, on arrival, at weaning, before moving to group pens, or with cows and heifers prefreshening
- INFORCE 3 can be used in beef herds in newborn calves and calves at branding, preconditioning, weaning, pre-shipment, or on arrival in stocker or feedlot operations.
Safe for all ages, types and classes of cattle
INFORCE 3 is safe for use in all types, ages and classes of cattle. INFORCE 3 was demonstrated safe for use in very young, high-stress calves, weaned and high-stress stocker calves, and pregnant heifers and cows.
The Science Behind Effective Control
- Intranasal administration works with the animal's immune system for fast, effective response
- Helps prime the immune system for a memory response to subsequent vaccinations as well as disease challenges
- Contains proprietary, temperature-sensitive IBR and PI3 strains that replicate most effectively in the upper respiratory tract
- Helps deliver a healthy start for young dairy and beef calves
References:
1 Animalytics data, 2015 to 2019.
2 Mahan SM, Sobecki B, Johnson J, et al. Efficacy of intranasal vaccination with a multivalent vaccine containing temperature-sensitive modified-live bovine herpesvirus type 1 for protection of seronegative and seropositive calves against respiratory disease. J Am Vet Med Assoc. 2016;248(11):1280-1286.
3 Ellis JA, Gow SP, Mahan S, Leyh R. Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves. J Am Vet Med Assoc. 2013;243(11):1602-1608.
4 Data on file. Study Report No. 3131R-60-08-557, Zoetis Inc.
5 Data on file. Study Report No. 3131R-60-09-669, Zoetis Inc.
6 Stokka GL, Neville B, Seeger JT, Stoltenow C, Dyer N, Gaspers JJ. Evaluation of the serologic effect of concurrent IBR, BRSV, PI3 and Mannheimia vaccination and time interval between the first and second dose on the subsequent serological response to the Mannheimia toxoid and BRSV fractions on spring-born beef calves in North Dakota. North Dakota Beef Report 2014;40-42.
7 Data on file, Study Report No. 3131R-60-08-548, Zoetis Inc.
8 Data on file, Study Report No. 3131R-60-09-720, Zoetis Inc.
9 Data on file, Study Report No. 3131R-60-08-568, Zoetis Inc.
10 Data on file, Study Report No. 10PETINF01, Zoetis Inc.